EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy and Safety of Intravenous Thrombolysis with Tenecteplase in Patients with Wake-Up Branch Atheromatous Disease

Lili Zhu, Ying Zhang, Jiarong Li, Liang Song, Haoran Li, Yang Yang, Lijuan Liu, Shaolei Zhang, Xiaofei Gao, Weifeng Chen, Guo Rui, Haiqiang Qin und 2 weitere

Translational Stroke Research · 2026-06 · 17 (3)

DOI: 10.1007/s12975-026-01443-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Translational Stroke Research, online erschienen am 01.05.2026. Verfasst von Lili Zhu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The Fifth Clinical Medical College of Henan, University of Chinese Medicine (Zhengzhou People's Hospital), No. 33 Huanghe Ro…. Hauptthemen laut MEDLINE: Tenecteplase, Fibrinolytic Agents, Thrombolytic Therapy, Ischemic Stroke. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Henan Province Medical Science and Technology Research Project, Henan Provincial Science and Technology Research Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Branch atheromatous disease (BAD), a subtype of acute ischemic stroke (AIS), is associated with a high risk of early neurological deterioration (END) and poor prognosis. Wake-up stroke (WUS), comprising 20%–30% of AIS cases, is typically excluded from thrombolysis because of unknown onset time. Using diffusion-weighted imaging/fluid-attenuated inversion recovery (DWI/FLAIR) mismatch, we evaluated the efficacy and safety of Tenecteplase (TNK) thrombolysis in patients with BAD-related WUS. We retrospectively recruited 1,062 patients from seven Zhengzhou hospitals between January 2021 and June 2025. The patients received either TNK (n = 338) or dual antiplatelet therapy (n = 724). Propensity score matching (PSM; 1:1, caliper 0.02) yielded 292 matched pairs. Early neurological changes were evaluated using the National Institutes of Health Stroke Scale (NIHSS), and 90-day outcomes were evaluated using the modified Rankin Scale (mRS). After PSM, TNK significantly reduced the risk of END (odds ratio [OR] = 0.425, 95% confidence interval [CI]: 0.262–0.689; P < 0.001). Patients treated with TNK were more likely to achieve good functional outcomes (modified Rankin Scale [mRS] 0–1 and 0–2) with fewer poor outcomes (mRS ≥ 4). There were no significant differences in symptomatic intracranial hemorrhage, other bleeding events, or mortality among the groups. DWI/FLAIR mismatch-guided TNK thrombolysis appears to overcome the limitations of an unknown onset time in WUS and may counteract the progressive pathophysiology of BAD. TNK intravenous thrombolysis may be a safe and effective treatment for patients with wake-up BAD and DWI/FLAIR mismatches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TenecteplaseFibrinolytic AgentsThrombolytic TherapyIschemic StrokePlaque, AtheroscleroticHumansFemaleMaleAgedRetrospective StudiesTreatment OutcomeMiddle AgedDiffusion Magnetic Resonance ImagingAged, 80 and overTissue Plasminogen Activator

Stichwörter der Autor:innen

Branch atheromatous diseaseDWI/FLAIR mismatchEarly neurological deteriorationIntravenous thrombolysisTenecteplaseWake-up stroke

Substanzen

TenecteplaseFibrinolytic AgentsTissue Plasminogen Activator

Autor:innen und Institutionen

  • Department of Neurology, The Fifth Clinical Medical College of Henan, University of Chinese Medicine (Zhengzhou People's Hospital), No. 33 Huanghe Road, Jinshui District, Zhengzhou, Henan Province, 450003, China.
  • Department of Neurology, Hopeshine-Minsheng Hospital of Xinzheng, No. 126, Jiefang North Road, Xinzheng City, Zhengzhou, 451100, China.
  • Department of Neurology, People's Hospital of Zhongmu, Zhongmu County, No. 64, Jiefang Road, Chengguan, Zhongmu, 451450, China.
  • Department of Neurology, Zhengzhou Zhongkang Hospital, No. 298, Nongye Road, Xinmi City, Zhengzhou, 450007, China.
  • Department of Neurology, Dengfeng People's Hospital, No. 2, Zhongyue Street, Dengfeng, 452470, China.
  • Department of Neurology, Xingyang People's Hospital, No. 22, Suohe West Road, Xingyang, 450100, China.

Förderung

  • Henan Province Medical Science and Technology Research Project
  • Henan Provincial Science and Technology Research Program

Zitieren

APA

Zhu, L., Zhang, Y., Li, J., Song, L., Li, H., Yang, Y., Liu, L., Zhang, S., Gao, X., Chen, W., Rui, G., Qin, H., Tian, M., & Fu, S. (2026). Efficacy and Safety of Intravenous Thrombolysis with Tenecteplase in Patients with Wake-Up Branch Atheromatous Disease. Translational Stroke Research, 17(3). https://doi.org/10.1007/s12975-026-01443-8

Vancouver

Zhu L, Zhang Y, Li J, Song L, Li H, Yang Y, et al. Efficacy and Safety of Intravenous Thrombolysis with Tenecteplase in Patients with Wake-Up Branch Atheromatous Disease. Translational Stroke Research. 2026;17(3). doi:10.1007/s12975-026-01443-8

BibTeX
@article{Zhu2026,
  author = {Zhu, Lili and Zhang, Ying and Li, Jiarong and Song, Liang and Li, Haoran and Yang, Yang and Liu, Lijuan and Zhang, Shaolei and Gao, Xiaofei and Chen, Weifeng and Rui, Guo and Qin, Haiqiang and Tian, Mingbo and Fu, Shengqi},
  title = {Efficacy and Safety of Intravenous Thrombolysis with Tenecteplase in Patients with Wake-Up Branch Atheromatous Disease},
  journal = {Translational Stroke Research},
  year = {2026},
  volume = {17},
  number = {3},
  doi = {10.1007/s12975-026-01443-8}
}
Kostenlos starten →